Kevin Kaiserman, MD

Kevin Kaiserman, MD, is senior vice president and therapeutic area head for diabetes at MannKind Corporation.

Articles by Kevin Kaiserman, MD

INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD

June 6th 2026

ADA 2026: Inhaled insulin (Afrezza) shows comparable HbA1c and time-in-range to rapid-acting analogs in youth, with greater treatment satisfaction reported.

First FDA-Approved Inhaled Insulin for Kids Arrives With Mounting Data: Kevin Kaiserman, MD

ByGiuliana Grossi,Kevin Kaiserman, MD

June 5th 2026

After FDA approval for children 6 and older, ADA data show inhaled insulin's safety and satisfaction benefits, but clinician awareness remains a key barrier.

Kevin Kaiserman, MD

Articles by Kevin Kaiserman, MD

INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD

First FDA-Approved Inhaled Insulin for Kids Arrives With Mounting Data: Kevin Kaiserman, MD

Latest Updated Articles

Trending on AJMC

Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year

Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD

Bridging Science and Reality in Diabetes Care